Cargando…
Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human
Until recently, the role of factor XII (FXII) in hemostasis was not considered to be important since patients with FXII deficiency do not present with bleeding. The activation of FXII by agents including mast cells and platelet polyphosphates suggests that it may have a role in thrombogenesis. The i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835526/ https://www.ncbi.nlm.nih.gov/pubmed/29541637 http://dx.doi.org/10.3389/fmed.2018.00046 |
_version_ | 1783303833370230784 |
---|---|
author | Wilmot, Helen V. Hockley, Jason Rigsby, Peter Gray, Elaine |
author_facet | Wilmot, Helen V. Hockley, Jason Rigsby, Peter Gray, Elaine |
author_sort | Wilmot, Helen V. |
collection | PubMed |
description | Until recently, the role of factor XII (FXII) in hemostasis was not considered to be important since patients with FXII deficiency do not present with bleeding. The activation of FXII by agents including mast cells and platelet polyphosphates suggests that it may have a role in thrombogenesis. The inhibition of FXII therefore presents an option for antithrombotic therapy, and antibodies and inhibitors are already in development. Assays for FXII will be required to support these technologies, and an international standard (IS) for FXII would be useful for the development of these methods and for the clinical monitoring of patients. The purpose of this study was to develop an IS for FXII, with values for functional activity (FXII:C) and antigen (FXII:Ag). Double-spun normal plasma was pooled, filled into siliconized glass ampoules, and freeze-dried to prepare the candidate material. Data from 20 laboratories using the one-stage clotting assay were used to assign the functional activity value in units (u). The antigen value was calculated using data from eight laboratories that carried out antigen assays. Each laboratory was requested to collect two local normal plasma pools. Units of activity and antigen were calculated relative to these pools, as is usual for new coagulation factor analytes. The amount of activity or antigen in 1 ml of normal plasma from each pool was taken to be 1 unit. A total of 566 donors were used across the pools for the FXII:C study and 216 donors for the FXII:Ag study. The overall geometric mean per ampoule for FXII:C was 0.86 u and for FXII:Ag was 0.80 u. The inter-laboratory variation was 10 and 11%, respectively (expressed as the geometric coefficient of variation). Based on these data, the candidate was deemed suitable for use as an IS for FXII. In 2017, the candidate was established by the World Health Organization (WHO) Expert Committee on Biological Standardization as the WHO first IS for blood coagulation FXII, Plasma (National Institute for Biological Standards and Control code 15/180). The values assigned were 0.86 international units (IU) of functional activity (FXII:C) per ampoule and 0.80 IU/ampoule of antigen (FXII:Ag). |
format | Online Article Text |
id | pubmed-5835526 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58355262018-03-14 Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human Wilmot, Helen V. Hockley, Jason Rigsby, Peter Gray, Elaine Front Med (Lausanne) Medicine Until recently, the role of factor XII (FXII) in hemostasis was not considered to be important since patients with FXII deficiency do not present with bleeding. The activation of FXII by agents including mast cells and platelet polyphosphates suggests that it may have a role in thrombogenesis. The inhibition of FXII therefore presents an option for antithrombotic therapy, and antibodies and inhibitors are already in development. Assays for FXII will be required to support these technologies, and an international standard (IS) for FXII would be useful for the development of these methods and for the clinical monitoring of patients. The purpose of this study was to develop an IS for FXII, with values for functional activity (FXII:C) and antigen (FXII:Ag). Double-spun normal plasma was pooled, filled into siliconized glass ampoules, and freeze-dried to prepare the candidate material. Data from 20 laboratories using the one-stage clotting assay were used to assign the functional activity value in units (u). The antigen value was calculated using data from eight laboratories that carried out antigen assays. Each laboratory was requested to collect two local normal plasma pools. Units of activity and antigen were calculated relative to these pools, as is usual for new coagulation factor analytes. The amount of activity or antigen in 1 ml of normal plasma from each pool was taken to be 1 unit. A total of 566 donors were used across the pools for the FXII:C study and 216 donors for the FXII:Ag study. The overall geometric mean per ampoule for FXII:C was 0.86 u and for FXII:Ag was 0.80 u. The inter-laboratory variation was 10 and 11%, respectively (expressed as the geometric coefficient of variation). Based on these data, the candidate was deemed suitable for use as an IS for FXII. In 2017, the candidate was established by the World Health Organization (WHO) Expert Committee on Biological Standardization as the WHO first IS for blood coagulation FXII, Plasma (National Institute for Biological Standards and Control code 15/180). The values assigned were 0.86 international units (IU) of functional activity (FXII:C) per ampoule and 0.80 IU/ampoule of antigen (FXII:Ag). Frontiers Media S.A. 2018-02-28 /pmc/articles/PMC5835526/ /pubmed/29541637 http://dx.doi.org/10.3389/fmed.2018.00046 Text en Copyright © 2018 Wilmot, Hockley, Rigsby and Gray. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Wilmot, Helen V. Hockley, Jason Rigsby, Peter Gray, Elaine Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human |
title | Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human |
title_full | Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human |
title_fullStr | Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human |
title_full_unstemmed | Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human |
title_short | Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human |
title_sort | establishment of the world health organization first international standard for factor xii, plasma, human |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835526/ https://www.ncbi.nlm.nih.gov/pubmed/29541637 http://dx.doi.org/10.3389/fmed.2018.00046 |
work_keys_str_mv | AT wilmothelenv establishmentoftheworldhealthorganizationfirstinternationalstandardforfactorxiiplasmahuman AT hockleyjason establishmentoftheworldhealthorganizationfirstinternationalstandardforfactorxiiplasmahuman AT rigsbypeter establishmentoftheworldhealthorganizationfirstinternationalstandardforfactorxiiplasmahuman AT grayelaine establishmentoftheworldhealthorganizationfirstinternationalstandardforfactorxiiplasmahuman |